Format

Send to

Choose Destination
Endocr Relat Cancer. 2019 Apr 1;26(4):411-423. doi: 10.1530/ERC-18-0507. Epub 2019 Jan 1.

UCHL1 loss alters the cell-cycle in metastatic pancreatic neuroendocrine tumors.

Author information

1
B Finnerty, Surgery, Cornell University Joan and Sanford I Weill Medical College, New York, United States.
2
M Moore, Surgery, Cornell University Joan and Sanford I Weill Medical College, New York, United States.
3
A Verma, Physiology and Biophysics, Cornell University Joan and Sanford I Weill Medical College, New York, United States.
4
A Aronova, Surgery, Cornell University Joan and Sanford I Weill Medical College, New York, United States.
5
S Huang, Molecular and Cellular Biology, Dan L. Duncan Cancer Center at Baylor College of Medicine , Houston, United States.
6
D Edwards, Molecular and Cellular Biology, Dan L. Duncan Cancer Center at Baylor College of Medicine, Houston, United States.
7
Z Chen, Healthcare Policy and Research, Cornell University Joan and Sanford I Weill Medical College, New York, United States.
8
M Seandel, Surgery, Cornell University Joan and Sanford I Weill Medical College, New York, United States.
9
T Scognamiglio, Pathology and Laboratory Medicine, Cornell University Joan and Sanford I Weill Medical College, New York, United States.
10
N Du, Pathology and Laboratory Medicine, Cornell University Joan and Sanford I Weill Medical College, New York, United States.
11
O Elemento, Physiology and Biophysics, Cornell University Joan and Sanford I Weill Medical College, New York, United States.
12
R Zarnegar, Surgery, Cornell University Joan and Sanford I Weill Medical College, New York, United States.
13
I Min, Surgery, Cornell University Joan and Sanford I Weill Medical College, New York, United States.
14
T Fahey, Surgery, Cornell University Joan and Sanford I Weill Medical College, New York, United States.
#
Contributed equally

Abstract

Loss of ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) expression by CpG promoter hypermethylation is associated with metastasis in gastroenteropancreatic neuroendocrine tumors; however, the mechanism of how UCHL1 loss contributes to metastatic potential remains unclear. In this study, we first confirmed that loss of UCHL1 expression on immunohistochemistry was significantly associated with metastatic tumors in a translational pancreatic neuroendocrine tumor (PNET) cohort, with a sensitivity and specificity of 78% and 89%, respectively. To study the mechanism driving this aggressive phenotype, BON and QGP-1 metastatic PNET cell lines, which do not produce UCHL1, were stably transfected to re-express UCHL1. In vitro assays, RNA-sequencing, and reverse-phase protein array (RPPA) analyses were performed comparing empty-vector negative controls and UCHL1-expressing cell lines. UCHL1 re-expression is associated with lower anchorage-independent colony growth in BON cells, lower colony formation in QGP cells, and a higher percentage of cells in the G0/G1 cell-cycle phase in BON and QGP cells. On RPPA proteomic analysis, there was an upregulation of cell-cycle regulatory proteins CHK2 (1.2 fold change, p=0.004) and P21 (1.2 fold change, p=0.023) in BON cells expressing UCHL1; western blot confirmed upregulation of phosphorylated CHK2 and P21. There were no transcriptomic differences detected on RNA-Sequencing between empty-vector negative controls and UCHL1-expressing cell lines. In conclusion, UCHL1 loss correlates with metastatic potential in PNETs and its re-expression induces a less aggressive phenotype in vitro, in part by inducing cell-cycle arrest through post-translational regulation of phosphorylated CHK2. UCHL1 re-expression should be considered as a functional biomarker in detecting PNETs capable of metastasis.

PMID:
30689542
DOI:
10.1530/ERC-18-0507

Supplemental Content

Full text links

Icon for Sheridan PubFactory
Loading ...
Support Center